31. (CTIC) - 3.2x Potential Upside On A De-Risked Asset

Strong Buy - Nizar Assanie 
Nizar Assanie is a Hedge Fund Manager and Private Investor with a background in Technology, Telecoms, and Biotech Investments.
https://seekingalpha.com/article/4506981-cti-biopharma-is-a-strong-buy

현직자'S 교차검증: 약장수 + 미국 혈액종양내과 현직자 의견(Twitter, investing)
조병학 단권화 / Risks: SEC에서 Risk 섹션 읽을 것
INCY가 Pfizer 같이 FDA의 BOD 장악여부 + 방해공작 가능성 신중히 검토할 것

투자 검토 대상: TSLA, CTIC, (달러 Short 3X), 밀wheat ETF, 금리인상 ETF(PFIX)

Summary

• CTIC is undervalued and a strong buy for new investors. The current share price of ~$5.63 does not reflect the potential of outsized 대형의 returns to patient, long-term investors.
• Under conservative assumptions, my DCF model shows the equity value of CTIC at $17 per fully diluted share, a ~3.2x ROI from current levels.
• VONJO's closest competitor (INCY's JAKAFI) is not indicated for blood platelet 혈소판 counts under 50 x10^9 /L. This makes VONJO a highly differentiated product.
  - INCY = Incyte Corporation
• My unit economics assume sales only in the U.S., VONJO achieving 55% market share of U.S. patients only in 2027, and only 20% of the patient population being first-line patients.

투자 검토 대상: TSLA, CTIC, (달러 Short 3X), 밀wheat ETF, 금리인상 ETF(PFIX)

1. 밀wheat ETF = WEAT
- 원자재는 무섭고 자신이 없다.

2. 금리인상 ETF(PFIX)
- 5년물 채권이 40%이고 나머지는 상품도 잘 이해안되는데,
- 매도시점을 잘 잡을 수 있을까?
- 향후 움직임이 예측이 되긴 할까?